About Menten AI
Menten AI is a biotechnology company pioneering the use of generative artificial intelligence to design cyclic peptide therapeutics for drug targets that lie beyond the reach of traditional small molecules and biologics. The company's proprietary platform, MAUD 1.0 (Multi-parametric AI for Unbiased Design), combines generative AI, physics-based modeling, and quantum simulations to design peptide macrocycles from scratch with atomic precision. Unlike traditional machine learning approaches that require large training datasets, MAUD 1.0 leverages physics-informed reinforcement learning to perform de novo design of cyclic peptides. The platform addresses a critical gap in drug discovery: up to 80% of drug targets, particularly protein-protein interfaces, cannot be effectively targeted by conventional therapeutics. Peptide macrocycles occupy a unique therapeutic space between small molecules and biologics, offering advantages such as high selectivity, low toxicity, and the ability to bind protein-protein interfaces. MAUD 1.0 has demonstrated the ability to design peptides with nanomolar-level potency, oral bioavailability exceeding 18%, cell permeability, and hit rates above 90%. Menten AI partners with top-10 pharmaceutical companies and is backed by leading venture capital firms. The company's technology enables multiple applications including oral peptides, cell-permeable peptides for intracellular targets, molecular glues, bi-specifics, and computational optimization. Their approach accelerates the preclinical discovery pipeline by designing and optimizing drug-like peptides more efficiently than traditional screening methods, expanding the accessible chemical space for therapeutic development.
Mission & Story
Mission
Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines
Founding Story
Founded by pioneers in computational drug design, including CEO Hans Melo (PhD in Machine Learning & Computational Neuroscience) and Academic Co-Founder Vikram Mulligan (PhD in Biochemistry, Core Developer of Rosetta software)
Clinical Focus
Medical conditions and clinical areas addressed by Menten AI.
Who It Serves
Milestones & Awards
Recent Milestones
MAUD 1.0 platform validated and operational with top-10 pharma partnerships established. Multiple scientific publications in 2024-2026 demonstrating platform capabilities.
Awards & Recognition
Y Combinator backed company. Featured in C&EN cover story on peptide macrocycles (June 2024). Selected for BioEurope 2025 Innovation Showcase.
Key Partnerships
Social & Media
Latest Updates
CompanyNews
3mo ago
March 31, 2026Interview with Hans Melo - Oxford GlobalHans Melo was interviewed by Cerlin Roberts for Oxford Global.Read more
3mo ago
March 25, 2026Menten AI presents at NextGen BioOur CEO, Hans Melo, headlined two major industry conferences this March, highlighting the transformative power of generative AI in drug discovery.Read more
3mo ago
January 1, 2026Menten AI Launches MAUD 1.0 PlatformMAUD 1.0 launches as Menten AI’s platform for AI-driven cyclic peptide design, combining generative AI and physics-based modeling to unlock hard-to-drug targets with potent, permeable therapeutics.Read more
6mo ago
Company Details
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.